| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CLINICAL STUDIES |
Departments of 1 , Cardiology and 2 Endocrinology, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart-Tilman, University of Liège, B-4000 Liège, Belgium
(Correspondence should be addressed to P Lancellotti; Email: plancellotti{at}chu.ulg.ac.be)
A Beckers (albert.beckers{at}chu.ulg.ac.be)
None of the authors report any conflicts of interest related to the study.
Aims: The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown.
Methods and results: We performed a cross-sectional, case–control echocardiographic study to assess the valvular status in 102 subjects receiving cabergoline for endocrine disorders and 51 matched control subjects. Cabergoline treatment ranged from 12 to 228 months, with a cumulative dose of 18–1718 mg. Valvular regurgitation was equally prevalent in both groups and was almost exclusively mild. Two cabergoline-treated subjects had moderate mitral regurgitation; there was no relationship between cabergoline dose and the presence or severity of mitral valve regurgitation (P=NS). Mitral valve tenting area was significantly greater in the cabergoline group when compared with the control subjects (P=0.03). Mitral valve leaflet thickening was observed in 5.9% of cabergoline-treated subjects; no relationship with the cumulative cabergoline dose was found. No patient had aortic or tricuspid valvular restriction.
Conclusion: No significantly increased risk of clinically relevant cardiac valve disorders was found in subjects treated with long-term cabergoline therapy at the doses used in endocrine practice. While exposure to cabergoline appears to be safe during low-dose long-term therapy, an association with subclinical changes in mitral valve geometry cannot be completely excluded.
This article has been cited by other articles:
|
|
 |
|
  S. Droogmans, D. Kerkhove, B. Cosyns, and G. Van Camp Role of echocardiography in toxic heart valvulopathy Eur J Echocardiogr, June 1, 2009; 10(4): 467 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sherlock, E. Fernandez-Rodriguez, A. A. Alonso, R. C. Reulen, J. Ayuk, R. N. Clayton, G. Holder, M. C. Sheppard, A. Bates, and P. M. Stewart Medical Therapy in Patients with Acromegaly: Predictors of Response and Comparison of Efficacy of Dopamine Agonists and Somatostatin Analogues J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1255 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M Martin, T. Tan, and K. Meeran Dopamine agonists and hyperprolactinaemia BMJ, March 3, 2009; 338(mar03_3): b381 - b381. [Full Text]
|
|
|
|
|
|
M. E. Molitch The Cabergoline-Resistant Prolactinoma Patient: New Challenges J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4643 - 4645. [Full Text] [PDF]
|
|
|
|
|
|
M. Ono, N. Miki, T. Kawamata, R. Makino, K. Amano, T. Seki, O. Kubo, T. Hori, and K. Takano Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4721 - 4727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Smith, J. Loeffler, M. Misra, S. R. Pomerantz, A. Stemmer-Rachamimov, and M. D. Post Case 37-2008 -- A 17-Year-Old Boy with a Pituitary Tumor and Skull Abnormalities N. Engl. J. Med., November 27, 2008; 359(22): 2367 - 2377. [Full Text] [PDF]
|
|
|
|
|
|
S. Droogmans, B. Cosyns, and G. Van Camp Pergolide and valvular heart disease: the lower the better? Eur J Echocardiogr, November 1, 2008; 9(6): 717 - 718. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wakil, A. S Rigby, A. L Clark, A. Kallvikbacka-Bennett, and S. L Atkin Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease Eur. J. Endocrinol., October 1, 2008; 159(4): R11 - R14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Kars, A M Pereira, J J Bax, and J A Romijn Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required Eur. J. Endocrinol., October 1, 2008; 159(4): 363 - 367. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
